GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT01715428

Completed

Liraglutide and Cardio-Metabolic Risk Markers

Effects of Liraglutide on Cardio-Metabolic Risk Markers

Lead sponsor

University of Palermo

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

300

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Carotid intima-media thickness

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01715428

Org study IDLIRAGLUTIDE UNIPA

Timeline

Milestones

Study first posted2012-10-29estimated

Last update posted2017-11-22actual

Study start2012-06actual (month precision)

Primary completion2015-12actual (month precision)

Study completion2015-12actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

Maximum age80 Years

SexAll

Healthy volunteersNot accepted

Sampling methodProbability sample

Study population text

adult subjects with type-2 diabetes

Inclusion criteria

- patients with a diagnosis of type-2 diabetes

Exclusion criteria

- severe hepatic or renal diseases

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers

Other (unclassified)

Cardiometabolic biomarkers

2 endpoints

Primary/protocol endpoint

carotid intima-media thickness

Time frame:every four months for a total period of 2 years

change from baseline, improvement

Secondary/protocol endpoint

changes in atherogenic lipoproteins

Time frame:after 2 and after 4 months of therapy

change from baseline, improvement

Other (unclassified)

2 endpoints

Secondary/protocol endpoint/low confidence

changes in oxidative stress markers

Time frame:after 2 months of therapy

change from baseline, improvement

Secondary/protocol endpoint/low confidence

changes in plasma ghrelin concentrations and heat-shock proteins

Time frame:after 2 months of therapy

change from baseline, descriptive

Publications (6)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study.
Diabetes therapy : research, treatment and education of diabetes and related disorders2022 Mar (month)PMID35167051doi:10.1007/s13300-022-01217-zvia clinicaltrials gov reference derived + pubmed nct search
Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect.
Diabetes therapy : research, treatment and education of diabetes and related disorders2021 Jan (month)PMID33210276doi:10.1007/s13300-020-00962-3via clinicaltrials gov reference derived + pubmed nct search
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.
Cardiovascular diabetology2016 Dec 3PMID27912784doi:10.1186/s12933-016-0480-8via clinicaltrials gov reference derived + pubmed nct search
Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study.
The Journal of clinical endocrinology and metabolism2015 Feb (month)PMID25393640doi:10.1210/jc.2014-2291via clinicaltrials gov reference derived + pubmed nct search
Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study.
Expert opinion on biological therapy2015 (year)PMID26195184doi:10.1517/14712598.2015.1067299via clinicaltrials gov reference derived + pubmed nct search
Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study.
Cardiovascular diabetology2014 Feb 22PMID24559258doi:10.1186/1475-2840-13-49via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.